×
About 7,375 results

ALLMedicine™ Familial Hypercholesterolemia Center

Research & Reviews  2,879 results

Finding Familial Hypercholesterolemia.
https://doi.org/10.1093/clinchem/hvaa316
Clinical Chemistry; Gidding SS

Apr 30th, 2021 - Finding Familial Hypercholesterolemia.|2021|Gidding SS,|

Reverse Cholesterol Transport Dysfunction Is a Feature of Familial Hypercholesterolemia.
https://doi.org/10.1007/s11883-021-00928-1 10.1093/eurheartj/eht273 10.1016/S0140-6736(12)62127-8 10.1016/j.molmed.2020.07.005 10.1111/j.1365-2796.2004.01405.x 10.1038/sj.ejhg.5201467 10.1055/s-2007-1003314 10.1161/ATVBAHA.111.227181 10.1097/MOL.0000000000000441 10.1016/j.atherosclerosis.2006.02.023 10.1016/j.jacl.2015.10.006 10.1016/0021-9150(88)90184-0 10.1016/j.jacc.2017.11.035 10.1016/S0022-2275(20)33394-0 10.1161/01.ATV.12.7.843 10.1161/01.ATV.7.4.401 10.1194/jlr.P061598 10.1016/j.jacl.2018.08.007 10.1161/CIRCRESAHA.119.316424 10.1161/ATVBAHA.109.193201 10.1128/MCB.23.6.2182-2191.2003 10.1056/NEJMoa1409065 10.1016/S2213-8587(15)00126-6 10.1093/jn/136.4.877 10.1161/ATVBAHA.115.306665 10.1016/j.atherosclerosis.2020.04.015 10.1016/j.jacc.2018.09.080 10.1161/CIRCRESAHA.120.317721 10.1161/01.ATV.14.5.679 10.1177/2047487319894114 10.1194/jlr.M031336 10.1161/ATVBAHA.116.307028 10.1038/nrm3313 10.1038/ncb2210 10.1016/j.cell.2004.12.035 10.1101/gr.082701.108 10.1128/MCB.01580-12 10.1073/pnas.1215767111 10.1042/CS20150235 10.1042/CS20171121 10.1126/science.1189862 10.1126/science.1189123 10.1073/pnas.1005191107 10.1194/jlr.M048819 10.1161/CIRCULATIONAHA.107.704254 10.1161/ATVBAHA.112.300263 10.1194/jlr.P016816 10.1194/jlr.M024141 10.1038/s41467-020-17915-w 10.1016/j.atherosclerosis.2016.05.005 10.1016/j.transci.2018.01.002 10.1016/j.atherosclerosis.2016.11.019 10.1016/j.atherosclerosis.2017.09.021 10.1161/ATVBAHA.114.303715 10.1016/j.atherosclerosis.2013.10.018 10.1016/j.ahj.2015.01.008 10.1016/j.atherosclerosis.2020.08.004
Current Atherosclerosis Reports; Escolà-Gil JC, Rotllan N et. al.

Apr 29th, 2021 - We seek to establish whether high-density lipoprotein HDL metabolism and reverse cholesterol transport (RCT) impairment is an intrinsic feature of familial hypercholesterolemia (FH). RCT from macrophages (m-RCT), a vascular cell type of major infl...

Polygenic risk scores: how much do they add?
https://doi.org/10.1097/MOL.0000000000000759
Current Opinion in Lipidology; Christoffersen M, Tybjærg-Hansen A

Apr 26th, 2021 - Current methods to assess genetic risk of familial hypercholesterolemia and coronary artery disease (CAD) focus on testing monogenic mutations in well known genes. Here we review recent developments in polygenic risk scores (PRSs) for LDL choleste...

A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia.
https://doi.org/10.1016/j.atherosclerosis.2021.03.042
Atherosclerosis Brandts J, Dharmayat KI et. al.

Apr 26th, 2021 - Several medications targeting PCSK9 reduce LDL-cholesterol (LDL-C) in heterozygous familial hypercholesterolemia (HeFH). We aimed to assess in patients diagnosed clinically as HeFH, whether LDL-C reduction varied by different therapeutic approache...

see more →

Guidelines  9 results

Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
https://esperion.gcs-web.com/node/11206/pdf

Feb 24th, 2020 - Esperion announced today that the U.S. Food and Drug Administration (FDA) approved NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. NEXLETOL is indicated as an adjunct to diet and maxima...

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Up...
https://doi.org/10.1016/j.cjca.2018.09.005
The Canadian Journal of Cardiology; Brunham LR, Ruel I et. al.

Dec 11th, 2018 - Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are...

Screening for Lipid Disorders in Children and Adolescents: Clinical Summary
https://allmedx.com/USPSTFPDF/lipidscreening_ch-summary.pdf

Aug 2nd, 2016 - Figure. Screening for Lipid Disorders in Children and Adolescents: Clinical Summary Population Asymptomatic children and adolescents 20 years or younger Recommendation No recommendation. Grade: I (insufficient evidence) Ri...

Familial hypercholesterolemia.
https://www.ncbi.nlm.nih.gov/pubmed/24335046
Journal of Atherosclerosis and Thrombosis; Teramoto T, Sasaki J et. al.

Dec 17th, 2013 - Familial hypercholesterolemia.|2013|Teramoto T,Sasaki J,Ishibashi S,Birou S,Daida H,|diagnosis,etiology,prevention & control,diagnosis,etiology,prevention & control,diagnosis,prevention & control,

NEXLETOL™ (bempedoic acid) - A New Treatment Option‎
https://www.nexletolhcp.com/

Discover How NEXLETOL May Help Appropriate Patients. See Important Safety Information and Full Prescribing Information. Learn About New Treatment. FDA Approved. Get The Facts.

see more →

Drugs  361 results see all →

Clinicaltrials.gov  3,653 results

Finding Familial Hypercholesterolemia.
https://doi.org/10.1093/clinchem/hvaa316
Clinical Chemistry; Gidding SS

Apr 30th, 2021 - Finding Familial Hypercholesterolemia.|2021|Gidding SS,|

Reverse Cholesterol Transport Dysfunction Is a Feature of Familial Hypercholesterolemia.
https://doi.org/10.1007/s11883-021-00928-1 10.1093/eurheartj/eht273 10.1016/S0140-6736(12)62127-8 10.1016/j.molmed.2020.07.005 10.1111/j.1365-2796.2004.01405.x 10.1038/sj.ejhg.5201467 10.1055/s-2007-1003314 10.1161/ATVBAHA.111.227181 10.1097/MOL.0000000000000441 10.1016/j.atherosclerosis.2006.02.023 10.1016/j.jacl.2015.10.006 10.1016/0021-9150(88)90184-0 10.1016/j.jacc.2017.11.035 10.1016/S0022-2275(20)33394-0 10.1161/01.ATV.12.7.843 10.1161/01.ATV.7.4.401 10.1194/jlr.P061598 10.1016/j.jacl.2018.08.007 10.1161/CIRCRESAHA.119.316424 10.1161/ATVBAHA.109.193201 10.1128/MCB.23.6.2182-2191.2003 10.1056/NEJMoa1409065 10.1016/S2213-8587(15)00126-6 10.1093/jn/136.4.877 10.1161/ATVBAHA.115.306665 10.1016/j.atherosclerosis.2020.04.015 10.1016/j.jacc.2018.09.080 10.1161/CIRCRESAHA.120.317721 10.1161/01.ATV.14.5.679 10.1177/2047487319894114 10.1194/jlr.M031336 10.1161/ATVBAHA.116.307028 10.1038/nrm3313 10.1038/ncb2210 10.1016/j.cell.2004.12.035 10.1101/gr.082701.108 10.1128/MCB.01580-12 10.1073/pnas.1215767111 10.1042/CS20150235 10.1042/CS20171121 10.1126/science.1189862 10.1126/science.1189123 10.1073/pnas.1005191107 10.1194/jlr.M048819 10.1161/CIRCULATIONAHA.107.704254 10.1161/ATVBAHA.112.300263 10.1194/jlr.P016816 10.1194/jlr.M024141 10.1038/s41467-020-17915-w 10.1016/j.atherosclerosis.2016.05.005 10.1016/j.transci.2018.01.002 10.1016/j.atherosclerosis.2016.11.019 10.1016/j.atherosclerosis.2017.09.021 10.1161/ATVBAHA.114.303715 10.1016/j.atherosclerosis.2013.10.018 10.1016/j.ahj.2015.01.008 10.1016/j.atherosclerosis.2020.08.004
Current Atherosclerosis Reports; Escolà-Gil JC, Rotllan N et. al.

Apr 29th, 2021 - We seek to establish whether high-density lipoprotein HDL metabolism and reverse cholesterol transport (RCT) impairment is an intrinsic feature of familial hypercholesterolemia (FH). RCT from macrophages (m-RCT), a vascular cell type of major infl...

Rosuvastatin calcium - rosuvastatin calcium tablet, film coated-American Health Packaging
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7491a1a-570e-40ea-b65b-f956c9e284a6

Apr 28th, 2021 - Pediatric use information for patients 7 to 17 years of age is approved for AstraZeneca’s CRESTOR (rosuvastatin calcium) tablets. However, due to AstraZeneca’s marketing exclusivity rights, this drug product is not labeled with that pediatric info...

Polygenic risk scores: how much do they add?
https://doi.org/10.1097/MOL.0000000000000759
Current Opinion in Lipidology; Christoffersen M, Tybjærg-Hansen A

Apr 26th, 2021 - Current methods to assess genetic risk of familial hypercholesterolemia and coronary artery disease (CAD) focus on testing monogenic mutations in well known genes. Here we review recent developments in polygenic risk scores (PRSs) for LDL choleste...

see more →

News  469 results

An Expert's Guide to Managing Familial Hypercholesterolemia
https://www.medscape.com/viewarticle/948546

Apr 20th, 2021 - This transcript has been edited for clarity. Hi. I'm Seth Baum, a preventive cardiologist and clinical lipidologist in Boca Raton, Florida. I'm also the past president of the American Society for Preventive Cardiology and on the faculty at the Flo...

FDA Okays New Indication for Alirocumab in Homozygous FH
https://www.medscape.com/viewarticle/948580

Mar 31st, 2021 - The US Food and Drug Administration has approved alirocumab (Praluent, Regeneron Pharmaceuticals) injection as add-on therapy for adults with homozygous familial hypercholesterolemia, the agency announced. The proprotein convertase subtilisin/kexi...

Achilles Tendon Softness a New Tool to Diagnose FH
https://www.medscape.com/viewarticle/948460

Mar 30th, 2021 - Achilles tendon softness should be considered a new indicator of familial hypercholesterolemia, in addition to Achilles tendon thickness, researchers suggest. In a cross-sectional study that measured Achilles tendon thickness and elasticity (i. e

FDA Approves Orphan Drug Evinacumab-dgnb for Homozygous FH
https://www.medscape.com/viewarticle/945719

Feb 10th, 2021 - The US Food and Drug Administration has approved the fully human monoclonal antibody evinacumab-dgnb (Evkeeza, Regeneron Pharmaceuticals) for use on top of other cholesterol-modifying meds in patients aged 12 and older with homozygous familial hyp...

Evinacumab, Novel Lipid-Lowerer, Extends Promise in Phase 2 Results
https://www.medscape.com/viewarticle/941043

Nov 15th, 2020 - Treatment with evinacumab, an investigational lipid-lowering drug with a novel mechanism of action, safely led to roughly a halving of LDL cholesterol levels in patients with treatment-refractory hypercholesterolemia in a multicenter, phase 2 stud...

see more →

Patient Education  4 results see all →